Literature DB >> 20680399

Tumor vascular leakiness and blood volume estimates in oligodendrogliomas using perfusion CT: an analysis of perfusion parameters helping further characterize genetic subtypes as well as differentiate from astroglial tumors.

Jayant Narang1, Rajan Jain, Lisa Scarpace, Sona Saksena, Lonni R Schultz, Jack P Rock, Mark Rosenblum, Suresh C Patel, Tom Mikkelsen.   

Abstract

The purpose of this study was to determine the usefulness of perfusion CT (PCT) parameters particularly blood volume and neovascular permeability estimates (permeability surface area-product, PS) in the evaluation of oligodendrogliomas (OG), correlation with genetic subtypes of OGs (with or without loss of heterozygosity/LOH on 1p/19q) as well as comparison of perfusion parameters of OGs with astroglial tumors. Pre-operative PCT done in 21 patients with OGs was retrospectively correlated with our previously published PCT data for 32 patients with astroglial neoplasms (Jain R et al., AJNR Am J Neuroradiol 29:694-700, 2008). All OGs were also analyzed for genetic subtypes of with or without LOH. PCT parameters PS and cerebral blood volume (CBV) were obtained for the entire lesion and a statistical analysis done to correlate various histopathological variants. Low grade OGs (n = 13) showed slightly lower CBV (1.42 vs. 1.72 ml/100 g; P value 0.391) and PS (0.56 vs. 0.95 ml/100 g/min; P value 0.099) as compared to high grade OGs (n = 8), though not statistically significant. LOH positive OGs (n = 13) showed higher mean CBV (1.59 vs. 1.45; P value 0.712) and slightly lower PS (0.68 vs. 0.75; P value 0.718) as compared to LOH negative OGs (n = 8), although not statistically significant. Low grade OGs (n = 13) showed higher mean CBV 1.42 ml/100 g as compared to low grade astroglial tumors (n = 8) 0.95 ml/100 g (P value = 0.08), however no statistically significant difference was noted for PS (0.56 vs. 0.52 ml/100 g/min, P value 0.695). Statistically significant differences were observed in CBV and PS values of high grade OGs and high grade astroglial tumors with the high grade glial tumors showing higher mean CBV (2.79 vs. 1.72; P value 0.03) as well as higher PS (2.37 vs. 0.95; P value < 0.01), however this difference was not significant if only comparing grade III OGs with grade III astroglial tumors. PCT perfusion parameters including PS values do not help grade OGs despite showing a trend for higher CBV and PS in higher grade OGs. Similarly LOH positive OGs also showed slightly higher CBV, but again failed to reach any statistically significant level. Low grade OGs showed slightly higher CBV as compared to low grade astroglial tumors, whereas higher grade OGs showed significantly lower PS values as compared to higher grade astroglial tumors despite showing high CBV.

Entities:  

Mesh:

Year:  2010        PMID: 20680399     DOI: 10.1007/s11060-010-0317-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  38 in total

Review 1.  Clinical applications of intracranial perfusion MR imaging.

Authors:  M H Lev; B R Rosen
Journal:  Neuroimaging Clin N Am       Date:  1999-05       Impact factor: 2.264

Review 2.  Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment.

Authors:  D Fortin; G J Cairncross; R R Hammond
Journal:  Neurosurgery       Date:  1999-12       Impact factor: 4.654

3.  Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors.

Authors:  M Vittoria Spampinato; J Keith Smith; Lester Kwock; Matthew Ewend; John D Grimme; Daniel L A Camacho; Mauricio Castillo
Journal:  AJR Am J Roentgenol       Date:  2007-01       Impact factor: 3.959

4.  Vascular endothelial growth factor (VEGF) likely contributes to oligodendroglioma angiogenesis.

Authors:  C Christov; R K Gherardi
Journal:  Acta Neuropathol       Date:  1999-04       Impact factor: 17.088

Review 5.  Oligodendroglioma: pathology and molecular biology.

Authors:  Herbert H Engelhard; Ana Stelea; Elizabeth J Cochran
Journal:  Surg Neurol       Date:  2002-08

6.  First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis.

Authors:  Rajan Jain; Lisa Scarpace; Shehanaz Ellika; Lonni R Schultz; Jack P Rock; Mark L Rosenblum; Suresh C Patel; Ting-Yim Lee; Tom Mikkelsen
Journal:  Neurosurgery       Date:  2007-10       Impact factor: 4.654

7.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

Review 8.  Primary brain tumours in adults.

Authors:  Anthony Behin; Khe Hoang-Xuan; Antoine F Carpentier; Jean-Yves Delattre
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

9.  Oligodendrogliomas: the Mayo Clinic experience.

Authors:  E G Shaw; B W Scheithauer; J R O'Fallon; H D Tazelaar; D H Davis
Journal:  J Neurosurg       Date:  1992-03       Impact factor: 5.115

10.  Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.

Authors:  Gabriel Corteze Netto; Cristina Birlem Bleil; Arlete Hilbig; Lígia Maria Barbosa Coutinho
Journal:  Neuropathology       Date:  2008-02       Impact factor: 1.906

View more
  11 in total

Review 1.  Genetics and imaging of oligodendroglial tumors.

Authors:  Jonathan R Ellenbogen; Carol Walker; Michael D Jenkinson
Journal:  CNS Oncol       Date:  2015-10-19

2.  Differential diagnosis of oligodendroglial and astrocytic tumors using imaging results: the added value of perfusion MR imaging.

Authors:  Hyun Jung Yoon; Kook Jin Ahn; Song Lee; Jin Hee Jang; Hyun Seok Choi; So Lyung Jung; Bum Soo Kim; Shin Soo Jeun; Yong Kil Hong
Journal:  Neuroradiology       Date:  2017-05-26       Impact factor: 2.804

3.  Prediction of malignancy grading using computed tomography perfusion imaging in nonenhancing supratentorial gliomas.

Authors:  Takaaki Beppu; Makoto Sasaki; Kohsuke Kudo; Akira Kurose; Masaru Takeda; Hiroshi Kashimura; Akira Ogawa; Kuniaki Ogasawara
Journal:  J Neurooncol       Date:  2010-10-15       Impact factor: 4.130

4.  Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.

Authors:  German Reyes-Botero; Caroline Dehais; Ahmed Idbaih; Nadine Martin-Duverneuil; Marion Lahutte; Catherine Carpentier; Eric Letouzé; Olivier Chinot; Hugues Loiseau; Jerome Honnorat; Carole Ramirez; Elisabeth Moyal; Dominique Figarella-Branger; François Ducray
Journal:  Neuro Oncol       Date:  2013-12-18       Impact factor: 13.029

Review 5.  Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images.

Authors:  Armin Eilaghi; Timothy Yeung; Christopher d'Esterre; Glenn Bauman; Slav Yartsev; Jay Easaw; Enrico Fainardi; Ting-Yim Lee; Richard Frayne
Journal:  Biomark Cancer       Date:  2016-07-03

Review 6.  Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.

Authors:  Robin W Jansen; Paul van Amstel; Roland M Martens; Irsan E Kooi; Pieter Wesseling; Adrianus J de Langen; Catharina W Menke-Van der Houven van Oordt; Bernard H E Jansen; Annette C Moll; Josephine C Dorsman; Jonas A Castelijns; Pim de Graaf; Marcus C de Jong
Journal:  Oncotarget       Date:  2018-04-13

7.  Improved differentiation between high- and low-grade gliomas by combining dual-energy CT analysis and perfusion CT.

Authors:  Yoko Kaichi; Fuminari Tatsugami; Yuko Nakamura; Yasutaka Baba; Makoto Iida; Toru Higaki; Masao Kiguchi; So Tsushima; Fumiyuki Yamasaki; Vishwa Jeet Amatya; Yukio Takeshima; Kaoru Kurisu; Kazuo Awai
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

8.  Perfusion CT detects alterations in local cerebral flow of glioma related to IDH, MGMT and TERT status.

Authors:  Ke Wang; Yeming Li; Haiyang Cheng; Shenjie Li; Wei Xiang; Yang Ming; Ligang Chen; Jie Zhou
Journal:  BMC Neurol       Date:  2021-11-24       Impact factor: 2.474

Review 9.  Hemodynamic Imaging in Cerebral Diffuse Glioma-Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions.

Authors:  Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra
Journal:  Cancers (Basel)       Date:  2022-03-05       Impact factor: 6.639

Review 10.  The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Sarah Jost Fouke; Tammie Benzinger; Daniel Gibson; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.